findmyKOL

James Ewing, MD

Basic profile

Medical Oncology

ORCIDNone on fileNPI
RegionGlendale, AZ · WestSpecialtyMedical OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

James Ewing is an Oncology physician.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
72companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

5810 W Beverly Ln
Glendale, AZ 853061800

Telephone

623-312-3000

Provider last certified this registry record 17 Nov 2022.

View the NPPES registry record

Industry payments

72 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    54.8%
    Iron, parenteral preparations54.6%
    Ferric carboxymaltose100%
    Part B, office-administered23 patients
    Factor Xa inhibitor0.2%
    Eliquis86%Xarelto14%
    Part D<11 patients
  • Cancer & immunology

    16.9%
    PD-1 inhibitor15.9%
    Pembrolizumab100%
    Part B, office-administered12 patients
    Gonadotropin Releasing Hormone Receptor Agonist0.3%
    Leuprolide acetate100%
    Part B, office-administered22 patients

    + 8 more classes in this area

  • Anti-infectives

    12.6%
    Human Immunoglobulin G12.5%
    Immune globulin100%
    Part B, office-administered11 patients
    Short-acting sulfonamides0.1%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”